Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Q1 2023 Earnings Presentation
9 slides from Sanara Medtech's earnings presentation, May 12, 2023
Slide 1: Q1 2023 Earnings and Business Update Call
Q1 2023 Earnings and Business Update Call
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements othe
Slide 3: Overview
Overview Commentary on Q1 2023 • Financial Update • Highest net revenue quarter in the Company’s history ($15.5 million). • March was the highest sales month in the Company’s history. • Net loss of $1.2 million in Q1 2023 compared to a net loss of $3.2 million in Q1 2022. • Innovation • On March 16,
Slide 4: Surgical Sales
Surgical Sales Sales Overview • Our products were sold in over 800 hospitals/ASCs across 30 states(1) in the TTM • Our products were contracted or approved to be sold in more than 1,800 hospitals/ASCs as of March 31, 2023. • Allocyte® sales slowed by limited supply of qualifying donor tissue. • Subs
Slide 5: BIASURGE – Product Launch
BIASURGE – Product Launch Launch Details • Product is 510(k) cleared and product launch is estimated to occur in late 2023. • Launch timing impacted and dependent on supply chain issues • Currently scheduling manufacturing runs • Currently developing marketing plan 5
Slide 6: Precision Healing Multispectral Imager ("MSI")
Precision Healing Multispectral Imager (“MSI”) Precision Healing Imager Indications for Use: • The MSI is a handheld imaging tool that allows clinicians diagnosing and treating skin wounds to: • View and digitally record multispectral and white light images of a wound. • Measure and digitally record
Slide 7: Q1 2023 Financial Highlights
Q1 2023 Financial Highlights Overview • Revenue • For the three months ended March 31, 2023, Sanara generated net revenues of $15.5 million compared to net revenues of $7.8 million for the three months ended March 31, 2022, a 99% increase from the prior year. • Net revenues for the three months ende
Slide 8: 2022 Financial Highlights (Continued)
2022 Financial Highlights (Continued) Overview (Continued) • Change in fair value of earnout liabilities • Change in fair value of earnout liabilities was a benefit of $0.5 million for the three months ended March 31, 2023 as a result of a decrease in the fair value of the earnout liabilities. • The
Slide 9: Questions
Questions Evidence Based Healing